TickerHumSide-by-side comparison
Abbott Laboratories vs Regeneron Pharmaceuticals
As of Nov 11, 2026, P/E is 40.6x for Abbott Laboratories vs 21.2x for Regeneron Pharmaceuticals; revenue growth is 10.0% for Abbott Laboratories vs 18.6% for Regeneron Pharmaceuticals; operating margin is 13.8% for Abbott Laboratories vs 28.8% for Regeneron Pharmaceuticals; net margin is 9.7% for Abbott Laboratories vs 28.5% for Regeneron Pharmaceuticals.
What stands out
- Regeneron Pharmaceuticals is cheaper on earnings: 21.2x P/E vs 40.6x for Abbott Laboratories.
- Regeneron Pharmaceuticals keeps more of each sale as operating profit: 28.8% margin vs 13.8% for Abbott Laboratories.
- Regeneron Pharmaceuticals carries less debt relative to equity: 0.06 vs 0.58 for Abbott Laboratories.
- Regeneron Pharmaceuticals's shares did better over the past year: +40.7% vs -15.2% for Abbott Laboratories.
Key metrics
| Metric | ABT | REGN |
|---|---|---|
| Price | $109.29 | $959.41 |
| Market cap | $189.28B | — |
| P/E | 40.6x (#2) | 21.2x (#1) |
| P/S | 3.9x (#1) | — |
| Revenue growth | 10.0% (#2) | 18.6% (#1) |
| Operating margin | 13.8% (#2) | 28.8% (#1) |
| Net margin | 9.7% (#2) | 28.5% (#1) |
| Debt / equity | 0.58 (#2) | 0.06 (#1) |
| 1-year return | -15.2% (#2) | +40.7% (#1) |
| Research score | 48/100 (#2) | 79/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Abbott Laboratories (ABT) — Medical Devices
- Regeneron Pharmaceuticals, Inc. (REGN) — Biotechnology